Collegium Pharmaceutical, Inc. (COLL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Ligand Pharmaceuticals, Inc.

Innoviva, Inc.

ImmunityBio, Inc.

Ardelyx, Inc.

Collegium Pharmaceutical, Inc.

Keros Therapeutics, Inc.

Revance Therapeutics, Inc.

Day One Biopharmaceuticals, Inc.

ACELYRIN, Inc.

Morphic Holding, Inc.

EQRx, Inc.

Why is Collegium Pharmaceutical, Inc. ?

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55
The company has been able to generate a Return on Capital Employed (avg) of 18.24% signifying low profitability per unit of total capital (equity and debt)

The company has declared negative results in Jun'2026 after 3 consecutive positive quarters

INTEREST(Q) At USD 19.52 MM has Grown at 23.06%
INTEREST COVERAGE RATIO(Q) Lowest at 361.93
INVENTORY TURNOVER RATIO(HY) Lowest at 4.27 times

Below par performance in long term as well as near term

Along with generating -37.03% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Collegium Pharmaceutical, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Collegium Pharmaceutical, Inc.

-37.03%

-0.71

44.75%

S&P 500

15.36%

1.17

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

20.28%

EBIT Growth (5y)

26.76%

EBIT to Interest (avg)

1.55

Debt to EBITDA (avg)

3.22

Net Debt to Equity (avg)

3.17

Sales to Capital Employed (avg)

0.61

Tax Ratio

32.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

18.24%

ROE (avg)

24.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.51

EV to EBIT

8.61

EV to EBITDA

3.86

EV to Capital Employed

1.91

EV to Sales

2.03

PEG Ratio

Dividend Yield

ROCE (Latest)

22.24%

ROE (Latest)

25.00%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 329.92 MM

-22What is not working for the Company

INTEREST(Q)

At USD 19.52 MM has Grown at 23.06%

INTEREST COVERAGE RATIO(Q)

Lowest at 361.93

INVENTORY TURNOVER RATIO(HY)

Lowest at 4.27 times

OPERATING PROFIT(Q)

Lowest at USD 70.64 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 35.34 %

PRE-TAX PROFIT(Q)

Lowest at USD -11.35 MM

NET PROFIT(Q)

Lowest at USD -12.87 MM

EPS(Q)

Lowest at USD -0.46

Here's what is working for Collegium Pharmaceutical, Inc.

Operating Cash Flow

Highest at USD 329.92 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Depreciation

Highest at USD 64.77 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Collegium Pharmaceutical, Inc.

Pre-Tax Profit

At USD -11.35 MM has Fallen at -135.53%

over average net sales of the previous four periods of USD 31.95 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -12.87 MM has Fallen at -159.26%

over average net sales of the previous four periods of USD 21.71 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 19.52 MM has Grown at 23.06%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest Coverage Ratio

Lowest at 361.93

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit

Lowest at USD 70.64 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at 35.34 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -11.35 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -12.87 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.46

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Lowest at 4.27 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio